KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Sarepta Therapeutics (SRPT) over the last 10 years, with Q2 2025 value amounting to $1.89.

  • Sarepta Therapeutics' EPS (Weighted Average and Diluted) rose 260000.0% to $1.89 in Q2 2025 from the same period last year, while for Jun 2025 it was $3.86, marking a year-over-year increase of 376000.0%. This contributed to the annual value of $2.34 for FY2024, which is 14034.48% up from last year.
  • Sarepta Therapeutics' EPS (Weighted Average and Diluted) amounted to $1.89 in Q2 2025, which was up 260000.0% from $1.56 recorded in Q4 2024.
  • Sarepta Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $1.89 during Q2 2025, with a 5-year trough of -$2.94 in Q3 2022.
  • Over the past 5 years, Sarepta Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.46 (recorded in 2023), while the average stood at -$0.46.
  • Per our database at Business Quant, Sarepta Therapeutics' EPS (Weighted Average and Diluted) crashed by 39000.0% in 2022 and then skyrocketed by 260000.0% in 2025.
  • Sarepta Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$1.43 in 2021, then grew by 13.29% to -$1.24 in 2022, then surged by 161.29% to $0.76 in 2023, then surged by 105.26% to $1.56 in 2024, then increased by 21.15% to $1.89 in 2025.
  • Its EPS (Weighted Average and Diluted) was $1.89 in Q2 2025, compared to $1.56 in Q4 2024 and $0.34 in Q3 2024.